Regulatory sanctions for ethically relevant GCP violations

Publication date

2019-11

Authors

Bernabe, Rosemarie de la Cruz
van Thiel, Ghislaine J.M.W.ORCID 0000-0003-1799-1894ISNI 000000039033919X
Breekveldt, Nancy S.
Gispen, Christine C.
van Delden, Johannes J.M.ISNI 000000002992622X

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by_nc_nd

Abstract

Although EU inspectors and clinical assessors are mandated to identify and act upon ethical issues, regulators lack guidance on how this can be done. Hence, we propose a four-step regulatory approach on ethically relevant GCP violation findings. The first step is identification of the ethical issue. Next is analysis [i.e., identifying the gravity (intensity or severity) and the magnitude (amount and duration) of the ethics violation as well as the responsible person(s) or entity or entities]. The third step is evaluation, (i.e., the process of deliberating to determine the significance of the ethics violation, with the intention of identifying the most reasonable sanction and/or corrective or reparative action). Last is decision-making or the process of choosing and implementing a regulatory course of action.

Keywords

Pharmacology, Drug Discovery

Citation

Bernabe, R D L C, van Thiel, G J M W, Breekveldt, N S, Gispen, C C & van Delden, J J M 2019, 'Regulatory sanctions for ethically relevant GCP violations', Drug Discovery Today, vol. 24, no. 11, pp. 2116-2119. https://doi.org/10.1016/j.drudis.2019.07.001